<p>MediWound（纳斯达克代码：MDWD - 获取免费报告）在华尔街 Zen 的股票分析师的研究报告中，将其评级从 “卖出” 上调至 “持有”。</p>
<p>其他几位股票分析师也对该公司发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 MediWound 的 “卖出（d-）” 评级。Zacks Research 在 11 月 11 日的研究报告中将 MediWound 的评级从 “强烈卖出” 上调至 “持有”。最后，HC Wainwright 在周五的研究报告中重新发布了 “买入” 评级，并将 MediWound 的目标价从 31.00 美元上调至 36.00 美元。四位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 33.50 美元。</p>
<p><strong>查看我们关于 MediWound 的最新报告</strong></p>
<h2>MediWound 股价上涨 1.2%</h2>
<p>MediWound 的股票在周五开盘价为 17.06 美元。该公司的 50 日移动平均价格为 18.02 美元，200 日移动平均价格为 18.83 美元。MediWound 的 1 年最低价为 14.14 美元，1 年最高价为 22.50 美元。该公司的市值为 1.8914 亿美元，市盈率为-6.46，贝塔值为 0.22。</p>
<p>MediWound（纳斯达克代码：MDWD - 获取免费报告）最近在 11 月 20 日宣布了其季度财报。这家生物制药公司报告本季度每股收益（EPS）为-0.24 美元，超出分析师共识预期的-0.81 美元，超出幅度为 0.57 美元。MediWound 的股本回报率为-96.71%，净利润率为-142.18%。该公司本季度的收入为 543 万美元，而共识预期为 656 万美元。股票研究分析师预测 MediWound 在当前财政年度的每股收益为-2.66 美元。</p>
<h2>MediWound 的机构交易</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Rosalind Advisors Inc.在第三季度将其在 MediWound 的持仓增加了 84.0%。Rosalind Advisors Inc.现在拥有 749,054 股生物制药公司的股票，价值 13,498,000 美元，此前在上个季度购买了 341,993 股。Meitav Investment House Ltd.在第三季度将其在 MediWound 的持股增加了 825.7%。Meitav Investment House Ltd.现在拥有 291,618 股生物制药公司的股票，价值 5,241,000 美元，此前在上个季度购买了 260,116 股。Millennium Management LLC 在第三季度将其在 MediWound 的持仓增加了 355.6%。Millennium Management LLC 现在拥有 175,383 股生物制药公司的股票，价值 3,160,000 美元，此前在上个季度购买了 136,884 股。Menora Mivtachim Holdings LTD.在第三季度将其在 MediWound 的持股增加了 348.8%。Menora Mivtachim Holdings LTD.现在拥有 78,539 股生物制药公司的股票，价值 1,415,000 美元，此前在上个季度购买了 61,039 股。最后，Clal Insurance Enterprises Holdings Ltd.在第三季度购买了 MediWound 的新持仓，价值约 1,042,000 美元。机构投资者持有该公司 46.83% 的股票。</p>
<h2>MediWound 公司简介</h2>
<p>（获取免费报告）</p>
<p>MediWound Ltd.是一家生物制药公司，开发、生产和商业化用于组织修复和再生的新型生物治疗和非手术解决方案，业务遍及美国、欧洲及国际市场。它市场上的 NexoBrid 是一种生物制药产品，用于去除成人深度部分和全层热烧伤患者的坏死组织，主要销售给烧伤中心和医院的烧伤科。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 MediWound</li>
<li>消费品股票解析</li>
<li>一项伟大的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>特殊目的收购公司（SPAC）你需要知道的事</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURXRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURXRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MediWound 吗？</h2>
<p>在考虑 MediWound 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MediWound 并不在名单上。</p>
<p>虽然 MediWound 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDWD

<p>华尔街禅将 MediWound（纳斯达克代码：MDWD）的评级从 “卖出” 上调至 “持有”。其他分析师的意见各不相同，有的维持 “卖出” 评级，有的则给予 “买入” 评级。该股票的共识评级为 “适度买入”，目标价格为 33.50 美元。MediWound 最近的财报超出预期，机构投资者也增加了在该公司的持仓。尽管评级为 “适度买入”，但顶级分析师建议比 MediWound 更好的投资选择</p>

<p>MediWound (NASDAQ:MDWD - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued to investors on Saturday.</p>
<div class="lb-trans"><p>MediWound（纳斯达克代码：MDWD - 获取免费报告）在华尔街 Zen 的股票分析师的研究报告中，将其评级从 “卖出” 上调至 “持有”。</p>
</div><p>Several other equities analysts have also issued reports on the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of MediWound in a research note on Wednesday, October 8th. Zacks Research upgraded shares of MediWound from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 11th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $33.50.</p>
<div class="lb-trans"><p>其他几位股票分析师也对该公司发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 MediWound 的 “卖出（d-）” 评级。Zacks Research 在 11 月 11 日的研究报告中将 MediWound 的评级从 “强烈卖出” 上调至 “持有”。最后，HC Wainwright 在周五的研究报告中重新发布了 “买入” 评级，并将 MediWound 的目标价从 31.00 美元上调至 36.00 美元。四位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 33.50 美元。</p>
</div><p><strong>View Our Latest Report on MediWound</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MediWound 的最新报告</strong></p>
</div><h2>MediWound Trading Up 1.2%</h2>
<div class="lb-trans"><h2>MediWound 股价上涨 1.2%</h2>
</div><p>Shares of MediWound stock opened at $17.06 on Friday. The business has a 50-day moving average price of $18.02 and a two-hundred day moving average price of $18.83. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50. The company has a market cap of $189.14 million, a P/E ratio of -6.46 and a beta of 0.22.</p>
<div class="lb-trans"><p>MediWound 的股票在周五开盘价为 17.06 美元。该公司的 50 日移动平均价格为 18.02 美元，200 日移动平均价格为 18.83 美元。MediWound 的 1 年最低价为 14.14 美元，1 年最高价为 22.50 美元。该公司的市值为 1.8914 亿美元，市盈率为-6.46，贝塔值为 0.22。</p>
</div><p>MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.57. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The company had revenue of $5.43 million for the quarter, compared to the consensus estimate of $6.56 million. Equities research analysts forecast that MediWound will post -2.66 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MediWound（纳斯达克代码：MDWD - 获取免费报告）最近在 11 月 20 日宣布了其季度财报。这家生物制药公司报告本季度每股收益（EPS）为-0.24 美元，超出分析师共识预期的-0.81 美元，超出幅度为 0.57 美元。MediWound 的股本回报率为-96.71%，净利润率为-142.18%。该公司本季度的收入为 543 万美元，而共识预期为 656 万美元。股票研究分析师预测 MediWound 在当前财政年度的每股收益为-2.66 美元。</p>
</div><h2>Institutional Trading of MediWound</h2>
<div class="lb-trans"><h2>MediWound 的机构交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. Rosalind Advisors Inc. lifted its position in shares of MediWound by 84.0% during the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company's stock valued at $13,498,000 after purchasing an additional 341,993 shares in the last quarter. Meitav Investment House Ltd. increased its stake in MediWound by 825.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company's stock valued at $5,241,000 after buying an additional 260,116 shares during the last quarter. Millennium Management LLC lifted its position in shares of MediWound by 355.6% during the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company's stock worth $3,160,000 after buying an additional 136,884 shares in the last quarter. Menora Mivtachim Holdings LTD. boosted its stake in shares of MediWound by 348.8% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company's stock worth $1,415,000 after buying an additional 61,039 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of MediWound in the 3rd quarter worth approximately $1,042,000. Institutional investors own 46.83% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Rosalind Advisors Inc.在第三季度将其在 MediWound 的持仓增加了 84.0%。Rosalind Advisors Inc.现在拥有 749,054 股生物制药公司的股票，价值 13,498,000 美元，此前在上个季度购买了 341,993 股。Meitav Investment House Ltd.在第三季度将其在 MediWound 的持股增加了 825.7%。Meitav Investment House Ltd.现在拥有 291,618 股生物制药公司的股票，价值 5,241,000 美元，此前在上个季度购买了 260,116 股。Millennium Management LLC 在第三季度将其在 MediWound 的持仓增加了 355.6%。Millennium Management LLC 现在拥有 175,383 股生物制药公司的股票，价值 3,160,000 美元，此前在上个季度购买了 136,884 股。Menora Mivtachim Holdings LTD.在第三季度将其在 MediWound 的持股增加了 348.8%。Menora Mivtachim Holdings LTD.现在拥有 78,539 股生物制药公司的股票，价值 1,415,000 美元，此前在上个季度购买了 61,039 股。最后，Clal Insurance Enterprises Holdings Ltd.在第三季度购买了 MediWound 的新持仓，价值约 1,042,000 美元。机构投资者持有该公司 46.83% 的股票。</p>
</div><h2>MediWound Company Profile</h2>
<div class="lb-trans"><h2>MediWound 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.</p>
<div class="lb-trans"><p>MediWound Ltd.是一家生物制药公司，开发、生产和商业化用于组织修复和再生的新型生物治疗和非手术解决方案，业务遍及美国、欧洲及国际市场。它市场上的 NexoBrid 是一种生物制药产品，用于去除成人深度部分和全层热烧伤患者的坏死组织，主要销售给烧伤中心和医院的烧伤科。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than MediWound</li>
<li>Consumer Staples Stocks, Explained</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MediWound</li>
<li>消费品股票解析</li>
<li>一项伟大的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>特殊目的收购公司（SPAC）你需要知道的事</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURXRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MDWD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MediWound Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MediWound 吗？</h2>
</div><p>Before you consider MediWound, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MediWound 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MediWound 并不在名单上。</p>
</div><p>While MediWound currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MediWound 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MediWound（NASDAQ:MDWD）在 Wall Street Zen 被提升评级